Stock DZ
04.06.2018 kl 22:34


***************Ongoing phase I study with fimaVACC in healthy volunteers*************
PCI Biotech is looking to validate its fimaVACC technology and assess the safety, tolerability and immune response in a clinical setting by conducting a phase I proof of principle study in healthy volunteers. The study is an open-label, antigen-adjuvant controlled study in up to 170 subjects. Healthy volunteers receive intradermal dosing of antigens (human papilloma virus E7 and Keyhole Limpet Hemocyanin (KLH)), the adjuvant hiltonol (poly-ICLC) and fimporfin (photosensitizer)followed by light application. Thereafter subjects are evaluated for adverse events, tolerability and the induction of immune response (blood samples).